Hyaluronan suppresses IL-1β-induced metalloproteinase activity from synovial tissue

Clinical Orthopaedics and Related Research

Volumn 465, Issue , 2007, Pages 241-248

  Waddell, David D ^a   Kolomytkin, Oleg V ^a   Dunn, Sharon ^b   Marino, Andrew A ^a,b  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; CD44 PROTEIN, HUMAN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HYPOTHESIS; KNEE PAIN; MOLECULAR WEIGHT; OSTEOARTHRITIS; PRIORITY JOURNAL; SYNOVIUM; VISCOSITY; BIOSYNTHESIS; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; ENZYME INDUCTION; ENZYMOLOGY; METABOLISM; PATHOLOGY; TISSUE CULTURE TECHNIQUE;

ANTIGENS, CD44; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; HUMANS; HYALURONIC ACID; INTERLEUKIN-1BETA; MATRIX METALLOPROTEINASES; MOLECULAR WEIGHT; OSTEOARTHRITIS; PROTEASE INHIBITORS; SYNOVIAL MEMBRANE; TISSUE CULTURE TECHNIQUES;

EID: 37349123227     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/BLO.0b013e31815873f9     Document Type: Article

References (33)

1. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl. 1993;39:3-9.
2. Culty M, Shizari M, Thompson EW, Underhill CB. Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential. J Cell Physiol. 1994;160:275-286.
3. Day AJ, Prestwich GD. Hyaluronan-binding proteins: tying up the giant. J Biol Chem. 2002;277:4585-4588.
4. Elkayam O, Yaron I, Shirazi I, Judovitch R, Caspi D, Yaron M. Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis. 2003;62:440-443.
5. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998;41:1343-1355.
6. Fuchs S, Dankbar B, Wildenau G, Goetz W, Lohmann CH, Tibesku CO. Expression of the CD44 variant isoform 5 in the human osteoarthritic knee joint: correlation with radiological, histomorphological, and biochemical parameters. J Orthop Res. 2004;22:774-780.
7. Ghosh P, Guidolin D. Potential mechanism of action of intraarticular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum. 2002;32:10-37.
8. Gomis A, Pawlak M, Balazs EA, Schmidt RF, Belmonte C. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum. 2004;50:314-326.
9. Greenberg DD, Stoker A, Kane S, Cockrell M, Cook JL. Biochemical effects of two different hyaluronic acid products in a co-culture model of osteoarthritis. Osteoarthritis Cartilage. 2006;14:814-822.
10. Haslinger B, Mandl-Weber S, Sellmayer A, Sitter T. Hyaluronan fragments induce the synthesis of MCP-1 and IL-8 in cultured human peritoneal mesothelial cells. Cell Tissue Res. 2001;305:79-86.
11. He W, Pelletier JP, Martel-Pelletier J, Laufer S, Di Battista JA. Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. J Rheumatol. 2002;29:546-553.
12. Hiramatsu T, Yasuda Y, Ito H, Shimizu M, Julovi SM, Kakinuma T, Akiyoshi M, Yoshida M, Nakamura T. Intercellular adhesion molecule-1 mediates the inhibitory effects of hyaluronan on interleukin-1-beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts via down-regulation of NF-kappaB and p38. Rheumatology (Oxford). 2006;45:824-832.
13. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis. 1957;16:494-502.
14. Kolomytkin OV, Marino AA, Sadasivan KK, Wolf RE, Albright JA. Intracellular signaling mechanisms of interleukin-1beta in synovial fibroblasts. Am J Physiol. 1999;276:C9-C15.
15. Kolomytkin OV, Marino AA, Waddell DD, Mathis JM, Wolf RE, Sadasivan KK, Albright JA. IL-1beta-induced production of metalloproteinases by synovial cells depends on gap-junction conductance. Am J Physiol Cell Physiol. 2002;282:C1254-C1260.
16. Lee YJ, Lee EB, Kwon YE, Lee JJ, Cho WS, Kim HA, Song YW. Effect of estrogen on the expression of matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13 and tissue inhibitor of metalloproternase-1 in osteoarthritis chondrocytes. Rheumatol Int. 2003;23:282-288.
17. Lee JY, Spicer AP. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol. 2000;12:581-586.
18. Lin N, Sato T, Takayama Y, Mimaki Y, Sashida Y, Yano M, Ito A. Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem Pharmacol. 2003;65:2065-2071.
19. Lindqvist U, Tolmachev V, Kairemo K, Aström G, Jonsson E, Lundqvist H. Elimination of stabilized hyaluronan from the knee joint in healthy men. Clin Pharmacokinet. 2002;41:603-613.
20. Mandelbaum B, Waddell D. Etiology and pathophysiology of osteoarthritis. Orthopedics. 2005;28(2 suppl):S207-S214.
21. Marino AA, Waddell DD, Kolomytkin OV, Meek WD, Wolf RE, Sadasivan KK, Albright JA. Increased intercellular communication through gap junctions may contribute to progression of osteoarthritis. Clin Orthop Relat Res. 2004;422:224-232.
22. Mengshol JA, Mix KS, Brinckerhoff CE. Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? Arthritis Rheum. 2002;46:13-20.
23. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
24. Ottaviani RA, Wooley P, Song Z, Markel DC. Inflammatory and immunological responses to hyaluronan preparations: study of a murine biocompatibility model. J Bone Joint Surg Am. 2007;89:148-157.
25. Pelletier JL, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001;44:1237-1247.
26. Powell JD, Horton MR. Threat matrix: low-molecular-weight hyaluronan (HA) as a danger signal. Immunol Res. 2005;31:207-218.
27. Shimizu M, Yasuda T, Nakagawa T, Yamashita E, Julovi SM, Hiramitsu T, Nakamura T. Hyaluronan inhibits matrix metalloproteinase-1 production by rheumatoid synovial fibroblasts stimulated by proinflammatory cytokines. J Rheumatol. 2003;30:1164-1172.
28. Singleton PA, Bourguignon LY. CD44v10 interaction with Rho-kinase (ROK) activates inositol 1,4,5-triphosphate (IP3) receptor-mediated Ca2+ signaling during hyaluronan (HA)-induced endothelial cell migration. Cell Motil Cytoskeleton. 2002;53:293-316.
29. Strober W. Trypan blue exclusion test of cell viability. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current Protocols in Immunology. New York, NY: John Wiley and Sons, Inc; 2003.
30. Takahashi K, Goomer RS, Harwood F, Kubo T, Hirasawa Y, Amiel D. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1B (IL-1beta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage. 1999;7:182-190.
31. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem. 2002;277:4589-4592.
32. Wang CT, Lin J, Chang CJ, Lin YT, Hou SM. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee: a meta-analysis of randomized controlled trials. J Bone Joint Surg Am. 2004;86:538-545.
33. Yoshimura K, Shigeura T, Matsumoto D, Sato T, Takaki Y, Aiba-Kojima E, Sato K, Inoue K, Nagase T, Koshima I, Gonda K. Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. J Cell Physiol. 2006;208:64-76.